Straits Times Index
3,204.82 +2.01 (+0.06%) Nikkei
32,402.41 -168.62 (-0.52%) Hang Seng
18,057.45 +402.04 (+2.28%) FTSE 100
7,683.91 +5.29 (+0.07%) Bitcoin USD
26,575.65 -19.69 (-0.07%) CMC Crypto 200
565.87 -2.18 (-0.38%)
Zentalis Pharmaceuticals, Inc. (ZNTL)
After hours:
| Previous close | 22.14 |
| Open | 22.13 |
| Bid | 21.28 x 1400 |
| Ask | 21.26 x 1300 |
| Day's range | 21.10 - 22.13 |
| 52-week range | 15.55 - 31.46 |
| Volume | |
| Avg. volume | 497,638 |
| Market cap | 1.502B |
| Beta (5Y monthly) | 1.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.76 |
| Earnings date | 07 Nov 2023 - 13 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 49.60 |
Motley FoolWhy Shares of Zentalis Pharmaceuticals Dropped This Week
Shares of Zentalis Pharmaceuticals (NASDAQ: ZNTL) were down 13.5% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence. The stock's prices were likely driven down by lowered investor sentiment due to a rash of insider selling. Zentalis is a clinical-stage biotech company that focuses on small-molecule therapies to treat cancer, specifically cancers with broad patient populations.
ZacksWall Street Analysts Believe Zentalis Pharmaceuticals, Inc. (ZNTL) Could Rally 95.67%: Here's is How to Trade
The consensus price target hints at a 95.7% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZacksCan Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 170.4% in Zentalis Pharmaceuticals, Inc. (ZNTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
